Feasibility of [11C]Acetate-Positron Emission Tomography (PET) in Lymphangioleiomyomatosis and Tuberous Sclerosis Complex
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study aims to assess [11C]acetate positron emission tomography (PET)/computed tomography
(CT) as a biomarker for renal angiomyolipomas and pulmonary lymphangioleiomyomatosis (LAM)
and an early biomarker of response to rapamycin in LAM patients.
[11C]acetate is a radioactive form of acetate, a nutrient commonly processed in our body's
cells to generate fat and energy. Preclinical studies support the hypothesis that TSC tumors
enhance lipid synthesis compared to normal tissues, suggesting that quantification of
[11C]acetate in these tumors by PET/CT may provide a metabolic biomarker of disease.
Participants in the study will undergo 1 or 2 PET/CT scans over 3 to 6 months at the
Massachusetts General Hospital (Boston, MA). [11C]acetate is administered through an
intravenous catheter. This small amount of radioactivity is short-lived and eliminated from
the body within a few hours.